{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T04:12:31Z","timestamp":1785211951261,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T00:00:00Z","timestamp":1707955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T00:00:00Z","timestamp":1707955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100011852","name":"Paracelsus Medical University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100011852","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Imaging Biol"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To assess the prognostic value of pre-treatment [<jats:sup>68<\/jats:sup>Ga]Ga-PSMA-11 PET\/CT and other baseline clinical characteristics in predicting prostate cancer (PCa) patients response to [<jats:sup>177<\/jats:sup>Lu]Lu-PSMA (PSMA-I&amp;T), as well as patient survival.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Procedures<\/jats:title>\n                <jats:p>In this retrospective study, 81 patients who received [<jats:sup>177<\/jats:sup>Lu]Lu-PSMA-I&amp;T between October 2018 and January 2023 were reviewed. Eligible patients had metastatic castration-resistant PCa, underwent pre-treatment [<jats:sup>68<\/jats:sup>Ga]Ga-PSMA-11 PET\/CT, and had serum prostate-specific antigen (PSA) levels available. On PET\/CT images, SUVmax, SULmax, SUVpeak, and SULpeak of the most-avid tumoral lesion, as well as SUVmean of the parotid gland (P-SUVmean) and liver (L-SUVmean), were measured. Also, whole-body PSMA tumour volume (PSMA-TV) and total lesion PSMA (TL-PSMA) were calculated. To interpret treatment response after [<jats:sup>177<\/jats:sup>Lu]Lu-PSMA-I&amp;T, a composite of PSA values and [<jats:sup>68<\/jats:sup>Ga]Ga-PSMA-11 PET\/CT findings were considered. The outcomes were dichotomised into progressive versus controlled (stable disease or partial response) disease. Then, the association of baseline parameters with patient response was evaluated. Also, survival analyses were performed to assess baseline parameters in predicting overall survival.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Sixty patients (age:73\u2009\u00b1\u20098, PSA:185\u2009\u00b1\u2009371) were included. Patients received at least one cycle of [<jats:sup>177<\/jats:sup>Lu]Lu-PSMA therapy (median\u2009=\u20094). Overall, half of the patients showed disease progression. In the progressive versus controlled disease evaluation, the highest SULmax, as well as SUVmax and SULmax to both backgrounds (L-SUVmean and P-SUVmean), were significantly correlated with the outcome (<jats:italic>p<\/jats:italic>-values\u2009&lt;\u20090.05). In the multivariate analysis, only SULmax to the L-SUVmean remained significant (<jats:italic>p<\/jats:italic>-value\u2009=\u20090.038). The best cut-off was 8 (AUC\u2009=\u20090.71). With a median follow-up of 360 days, 11 mortal events were documented. In the multivariate survival analysis, only SULmax to P-SUVmean (cut-off\u2009=\u20092.4; <jats:italic>p<\/jats:italic>-value\u2009=\u20090.043) retained significance (hazard ratio\u2009=\u20094.0).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>A greater level of PSMA uptake, specifically higher tumour-to-background uptake in the hottest lesion, may hold substantial prognostic significance, considering both [<jats:sup>177<\/jats:sup>Lu]Lu-PSMA-I&amp;T response and patient survival. These ratios may have the potential to be used for PCa patient selection for radioligand therapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11307-024-01900-6","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T18:02:16Z","timestamp":1708020136000},"page":"360-369","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Pre-treatment 68\u00a0Ga-PSMA-11 PET\/CT Prognostic Value in Predicting Response to 177Lu-PSMA-I&amp;T Therapy and Patient Survival"],"prefix":"10.1007","volume":"26","author":[{"given":"Roya","family":"Eisazadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Ali","family":"Mirshahvalad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Schwieghofer-Zwink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Hehenwarter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gundula","family":"Rendl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Gampenrieder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Greil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Pirich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3918-3812","authenticated-orcid":false,"given":"Mohsen","family":"Beheshti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,15]]},"reference":[{"key":"1900_CR1","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.eururo.2019.08.005","volume":"77","author":"MB Culp","year":"2020","unstructured":"Culp MB, Soerjomataram I, Efstathiou JA et al (2020) Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol 77:38\u201352","journal-title":"Eur Urol"},{"key":"1900_CR2","doi-asserted-by":"crossref","unstructured":"Rosar F, Wenner F, Khreish F et al (2022) Early molecular imaging response assessment based on determination of total viable tumor burden in [68Ga]Ga-PSMA-11 PET\/CT independently predicts overall survival in [177Lu]Lu-PSMA-617 radioligand therapy. Eur J Nucl Med Mol Imaging 49:1584\u20131594","DOI":"10.1007\/s00259-021-05594-8"},{"key":"1900_CR3","doi-asserted-by":"publisher","first-page":"153601211877606","DOI":"10.1177\/1536012118776068","volume":"17","author":"K Rahbar","year":"2018","unstructured":"Rahbar K, Afshar-Oromieh A, Jadvar H et al (2018) PSMA theranostics: current status and future directions. Mol Imaging 17:1536012118776068","journal-title":"Mol Imaging"},{"key":"1900_CR4","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","volume":"19","author":"MS Hofman","year":"2018","unstructured":"Hofman MS, Violet J, Hicks RJ et al (2018) [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol 19:825\u2013833","journal-title":"Lancet Oncol"},{"key":"1900_CR5","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.3390\/biom11081099","volume":"11","author":"F Khreish","year":"2021","unstructured":"Khreish F, Wiessner M, Rosar F et al (2021) Response assessment and prediction of progression-free survival by 68Ga-PSMA-11 PET\/CT based on tumor-to-liver ratio (TLR) in patients with mCRPC undergoing 177Lu-PSMA-617 radioligand therapy. Biomolecules 11:1099","journal-title":"Biomolecules"},{"key":"1900_CR6","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S et al (2021) [177Lu] Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet 397:797\u2013804","journal-title":"Lancet"},{"key":"1900_CR7","doi-asserted-by":"crossref","unstructured":"Morris MJ, De Bono JS, Chi KN et al (2021) Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION).\u00a0J Clin Oncol\u00a039:LBA4","DOI":"10.1200\/JCO.2021.39.15_suppl.LBA4"},{"key":"1900_CR8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.clgc.2018.09.014","volume":"17","author":"L Emmett","year":"2019","unstructured":"Emmett L, Crumbaker M, Ho B et al (2019) Results of a prospective phase 2 pilot trial of 177Lu\u2013PSMA-617 therapy for metastatic castration-resistant prostate cancer including imaging predictors of treatment response and patterns of progression. Clin Genitourin Cancer 17:15\u201322","journal-title":"Clin Genitourin Cancer"},{"key":"1900_CR9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2967\/jnumed.116.183194","volume":"58","author":"K Rahbar","year":"2017","unstructured":"Rahbar K, Ahmadzadehfar H, Kratochwil C et al (2017) German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med 58:85\u201390","journal-title":"J Nucl Med"},{"key":"1900_CR10","doi-asserted-by":"publisher","first-page":"4262","DOI":"10.1007\/s00259-022-05853-2","volume":"49","author":"PE Hartrampf","year":"2022","unstructured":"Hartrampf PE, Seitz AK, Weinzierl FX et al (2022) Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [177Lu] Lu-PSMA I&T during long-term follow-up. Eur J Nucl Med Mol Imaging 49:4262\u20134270","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1900_CR11","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1007\/s00259-020-05082-5","volume":"48","author":"S Rasul","year":"2021","unstructured":"Rasul S, Hartenbach M, Wollenweber T et al (2021) Prediction of response and survival after standardized treatment with 7400 MBq 177 Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging 48:1650\u20131657","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1900_CR12","doi-asserted-by":"publisher","first-page":"689","DOI":"10.2967\/jnumed.119.231431","volume":"61","author":"H Rathke","year":"2020","unstructured":"Rathke H, Holland-Letz T, Mier W et al (2020) Response prediction of 177Lu-PSMA-617 radioligand therapy using prostate-specific antigen, chromogranin A, and lactate dehydrogenase. J Nucl Med 61:689\u2013695","journal-title":"J Nucl Med"},{"key":"1900_CR13","doi-asserted-by":"publisher","first-page":"312","DOI":"10.2967\/jnumed.116.178228","volume":"58","author":"J Ferdinandus","year":"2017","unstructured":"Ferdinandus J, Eppard E, Gaertner FC et al (2017) Predictors of response to radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617. J Nucl Med 58:312\u2013319","journal-title":"J Nucl Med"},{"key":"1900_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-020-07192-7","volume":"20","author":"ML Donswijk","year":"2020","unstructured":"Donswijk ML, van Leeuwen PJ, Vegt E et al (2020) Clinical impact of PSMA PET\/CT in primary prostate cancer compared to conventional nodal and distant staging: a retrospective single center study. BMC Cancer 20:1\u201310","journal-title":"BMC Cancer"},{"key":"1900_CR15","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s00259-021-05616-5","volume":"49","author":"M Chavoshi","year":"2022","unstructured":"Chavoshi M, Mirshahvalad SA, Metser U et al (2022) 68Ga-PSMA PET in prostate cancer: a systematic review and meta-analysis of the observer agreement. Eur J Nucl Med Mol Imaging 49:1021\u20131029","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1900_CR16","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00259-020-04934-4","volume":"48","author":"S Fanti","year":"2021","unstructured":"Fanti S, Goffin K, Hadaschik BA et al (2021) Consensus statements on PSMA PET\/CT response assessment criteria in prostate cancer. Eur J Nucl Med Mol Imaging 48:469\u2013476","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1900_CR17","doi-asserted-by":"crossref","unstructured":"Gafita A, Djaileb L, Rauscher I et al (2023) Response evaluation criteria in PSMA PET\/CT (RECIP 1.0) in metastatic castration-resistant prostate cancer. Radiol 308:e222148.","DOI":"10.1148\/radiol.222148"},{"key":"1900_CR18","first-page":"1651","volume":"63","author":"A Gafita","year":"2022","unstructured":"Gafita A, Rauscher I, Weber M et al (2022) Novel framework for treatment response evaluation using PSMA PET\/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study. J Nucl Med 63:1651\u20131658","journal-title":"J Nucl Med"},{"key":"1900_CR19","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1007\/s00259-017-3670-z","volume":"44","author":"WP Fendler","year":"2017","unstructured":"Fendler WP, Eiber M, Beheshti M et al (2017) 68 Ga-PSMA PET\/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging 44:1014\u20131024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1900_CR20","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1007\/s00259-018-4042-z","volume":"45","author":"C Schmidkonz","year":"2018","unstructured":"Schmidkonz C, Cordes M, Schmidt D et al (2018) 68 Ga-PSMA-11 PET\/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer. Eur J Nucl Med Mol Imaging 45:1862\u20131872","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1900_CR21","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.2967\/jnumed.118.224055","volume":"60","author":"A Gafita","year":"2019","unstructured":"Gafita A, Bieth M, Kr\u00f6nke M et al (2019) qPSMA: semiautomatic software for whole-body tumor burden assessment in prostate cancer using 68Ga-PSMA11 PET\/CT. J Nucl Med 60:1277\u20131283","journal-title":"J Nucl Med"},{"key":"1900_CR22","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1007\/s00259-020-04723-z","volume":"47","author":"J Ferdinandus","year":"2020","unstructured":"Ferdinandus J, Violet J, Sandhu S et al (2020) Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617. Eur J Nucl Med Mol Imaging 47:2322\u20132327","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1900_CR23","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.3390\/biomedicines10071575","volume":"10","author":"EC van der Sar","year":"2022","unstructured":"van der Sar EC, K\u00fchr AJ, Ebbers SC et al (2022) Baseline imaging derived predictive factors of response following [177Lu] Lu-PSMA-617 therapy in salvage metastatic castration-resistant prostate cancer: a lesion-and patient-based analysis. Biomedicines 10:1575","journal-title":"Biomedicines"},{"key":"1900_CR24","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00259-020-04797-9","volume":"48","author":"H Ahmadzadehfar","year":"2021","unstructured":"Ahmadzadehfar H, Rahbar K, Baumbal. RP (2021) Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177 Lu] Lu-PSMA-617. A WARMTH multicenter study (the 617 trial). Eur J Nucl Med Mol imaging 48:113\u2013122","journal-title":"Eur J Nucl Med Mol imaging"},{"key":"1900_CR25","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.3390\/cancers13122938","volume":"13","author":"L Widjaja","year":"2021","unstructured":"Widjaja L, Werner RA, Ross TL et al (2021) PSMA expression predicts early biochemical response in patients with metastatic castration-resistant prostate cancer under 177Lu-PSMA-617 radioligand therapy. Cancers 13:2938","journal-title":"Cancers"},{"key":"1900_CR26","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.2967\/jnumed.115.168443","volume":"57","author":"RP Baum","year":"2016","unstructured":"Baum RP, Kulkarni HR, Schuchardt C et al (2016) 177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy. J Nucl Med 57:1006\u20131013","journal-title":"J Nucl Med"},{"key":"1900_CR27","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s00259-016-3481-7","volume":"44","author":"MP Yadav","year":"2017","unstructured":"Yadav MP, Ballal S, Tripathi M et al (2017) 177 Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment. Eur J Nucl Med Mol imaging 44:81\u201391","journal-title":"Eur J Nucl Med Mol imaging"},{"key":"1900_CR28","doi-asserted-by":"crossref","unstructured":"Hotta M, Gafita A, Murthy V et al (2023) PSMA PET tumor\u2013to\u2013salivary gland ratio to predict response to [177Lu]PSMA radioligand therapy: an international multicenter retrospective study. J Nucl Med 64:1024\u20131029","DOI":"10.2967\/jnumed.122.265242"},{"key":"1900_CR29","doi-asserted-by":"crossref","unstructured":"Karimzadeh A, Heck M, Tauber R et al (2023) The impact of PSMA PET\u2013based eligibility criteria used in the prospective phase II TheraP trial in metastatic castration-resistant prostate cancer patients undergoing prostate-specific membrane antigen\u2013targeted radioligand therapy. J Nucl Med 64:1252\u20131258","DOI":"10.2967\/jnumed.122.265346"},{"key":"1900_CR30","doi-asserted-by":"publisher","first-page":"20190380","DOI":"10.1259\/bjr.20190380","volume":"92","author":"S Suman","year":"2019","unstructured":"Suman S, Parghane RV, Joshi A et al (2019) Therapeutic efficacy, prognostic variables and clinical outcome of 177Lu-PSMA-617 PRLT in progressive mCRPC following multiple lines of treatment: prognostic implications of high FDG uptake on dual tracer PET-CT vis-\u00e0-vis Gleason score in such cohort. Brit J Radiol 92:20190380","journal-title":"Brit J Radiol"},{"key":"1900_CR31","doi-asserted-by":"publisher","first-page":"955","DOI":"10.2967\/jnumed.118.216820","volume":"60","author":"TW Barber","year":"2019","unstructured":"Barber TW, Singh A, Kulkarni HR et al (2019) Clinical outcomes of 177Lu-PSMA radioligand therapy in earlier and later phases of metastatic castration-resistant prostate cancer grouped by previous taxane chemotherapy. J Nucl Med 60:955\u2013962","journal-title":"J Nucl Med"}],"container-title":["Molecular Imaging and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-024-01900-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11307-024-01900-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-024-01900-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T16:20:32Z","timestamp":1711556432000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11307-024-01900-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,15]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["1900"],"URL":"https:\/\/doi.org\/10.1007\/s11307-024-01900-6","relation":{},"ISSN":["1536-1632","1860-2002"],"issn-type":[{"value":"1536-1632","type":"print"},{"value":"1860-2002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,15]]},"assertion":[{"value":"9 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was performed in accordance with the principles of the 1964 Declaration of Helsinki and its later amendments or comparable standards and approved by the ethics committee of the province with the trial number of \u201c1067\/2023\u201d.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"A signature of the written informed consent was obtained from all individuals in the clinical setting performing [<sup>68<\/sup>\u00a0Ga]Ga-PSMA-11 PET\/CT examinations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"Mohsen Beheshti reports a relationship with Novartis Pharma GmbH that includes board membership and consulting or advisory.Christian Pirich reports a relationship with Novartis Pharma GmbH that includes board membership and consulting or advisory.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}